BC Innovations | Jul 28, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Checkpoint kinase 2 (CHEK2; CHK2); MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2) In vitro and mouse studies suggest combining a CHK2 inhibitor...
BC Week In Review | Mar 7, 2011
Clinical News

Harbor BioSciences, China National Pharmaceutical Group preclinical data

In rats with induced mammary tumors, 6.6 mg/day Apoptone plus weekly Taxotere docetaxel for 28 days significantly inhibited tumor growth vs. Taxotere alone (p=0.0149), and with no apparent signs of toxicity. Furthermore, Apoptone plus Taxotere...
BC Week In Review | Feb 28, 2011
Clinical News

Harbor BioSciences preclinical data

In mice, >50% of levels of Triolex measured in plasma were found in the brains of mice after oral administration, which indicates that the compound is capable of crossing the blood-brain barrier (BBB). Triolex, a...
BC Week In Review | Feb 14, 2011
Clinical News

Apoptone: Phase I/IIa completed

Harbor completed an open-label, U.S. Phase I/IIa trial evaluating 10-700 mg/day Apoptone in 68 patients. Last September, Harbor reported data from 22 chemotherapy-naïve patients showing that 100 or 350 mg/day Apoptone produced 20 cases of...
BioCentury | Feb 7, 2011
Strategy

Networked in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking. In January, Ligand granted Chiva Pharmaceuticals Inc....
BC Week In Review | Jan 24, 2011
Company News

Harbor BioSciences, China National Pharmaceutical Group Corp. deal

Harbor granted China National Pharmaceutical Group's China State Institute of Pharmaceutical Industry (CIPI) subsidiary exclusive rights to develop and commercialize HE2000 , Apoptone ( HE3235 ) and Triolex ( HE3286 ) in China. HE2000, a 16alpha-bromoepiandrosterone against an unknown target,...
BC Week In Review | Oct 4, 2010
Clinical News

Apoptone: Additional Phase I/IIa data

Data from 22 chemotherapy-naïve patients in an ongoing, open-label Phase I/IIa trial showed that 100 or 350 mg/day Apoptone produced 20 cases of stable disease at 8 weeks, with 1 confirmed partial response at the...
BC Week In Review | Sep 27, 2010
Financial News

Harbor BioSciences financial update

Harbor BioSciences was delisted from NASDAQ for failure to comply with the exchange's listing requirements. The company is now listed on the OTC Bulletin Board under the same symbol. Harbor BioSciences Inc. (OTCBB: HRBR), San...
BC Week In Review | Jun 14, 2010
Financial News

Harbor BioSciences completes direct public offering

Harbor BioSciences Inc. (NASDAQ:HRBR), San Diego, Calif.   Business: Endocrine, Autoimmune, Cancer   Date completed: 6/7/10   Type: Direct public offering   Raised: $2.1 million   Units: 5.9 million   Price: $0.35 (unit)   Shares...
BC Week In Review | May 17, 2010
Clinical News

Triolex: Phase IIa data

Data from the first and second stages of the double-blind, 2-stage, U.S. Phase IIa HE3286-0401 trial showed that 5 mg twice-daily oral Triolex missed the primary endpoint of significantly reducing HbA1c from baseline to week...
Items per page:
1 - 10 of 174
BC Innovations | Jul 28, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Checkpoint kinase 2 (CHEK2; CHK2); MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2) In vitro and mouse studies suggest combining a CHK2 inhibitor...
BC Week In Review | Mar 7, 2011
Clinical News

Harbor BioSciences, China National Pharmaceutical Group preclinical data

In rats with induced mammary tumors, 6.6 mg/day Apoptone plus weekly Taxotere docetaxel for 28 days significantly inhibited tumor growth vs. Taxotere alone (p=0.0149), and with no apparent signs of toxicity. Furthermore, Apoptone plus Taxotere...
BC Week In Review | Feb 28, 2011
Clinical News

Harbor BioSciences preclinical data

In mice, >50% of levels of Triolex measured in plasma were found in the brains of mice after oral administration, which indicates that the compound is capable of crossing the blood-brain barrier (BBB). Triolex, a...
BC Week In Review | Feb 14, 2011
Clinical News

Apoptone: Phase I/IIa completed

Harbor completed an open-label, U.S. Phase I/IIa trial evaluating 10-700 mg/day Apoptone in 68 patients. Last September, Harbor reported data from 22 chemotherapy-naïve patients showing that 100 or 350 mg/day Apoptone produced 20 cases of...
BioCentury | Feb 7, 2011
Strategy

Networked in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking. In January, Ligand granted Chiva Pharmaceuticals Inc....
BC Week In Review | Jan 24, 2011
Company News

Harbor BioSciences, China National Pharmaceutical Group Corp. deal

Harbor granted China National Pharmaceutical Group's China State Institute of Pharmaceutical Industry (CIPI) subsidiary exclusive rights to develop and commercialize HE2000 , Apoptone ( HE3235 ) and Triolex ( HE3286 ) in China. HE2000, a 16alpha-bromoepiandrosterone against an unknown target,...
BC Week In Review | Oct 4, 2010
Clinical News

Apoptone: Additional Phase I/IIa data

Data from 22 chemotherapy-naïve patients in an ongoing, open-label Phase I/IIa trial showed that 100 or 350 mg/day Apoptone produced 20 cases of stable disease at 8 weeks, with 1 confirmed partial response at the...
BC Week In Review | Sep 27, 2010
Financial News

Harbor BioSciences financial update

Harbor BioSciences was delisted from NASDAQ for failure to comply with the exchange's listing requirements. The company is now listed on the OTC Bulletin Board under the same symbol. Harbor BioSciences Inc. (OTCBB: HRBR), San...
BC Week In Review | Jun 14, 2010
Financial News

Harbor BioSciences completes direct public offering

Harbor BioSciences Inc. (NASDAQ:HRBR), San Diego, Calif.   Business: Endocrine, Autoimmune, Cancer   Date completed: 6/7/10   Type: Direct public offering   Raised: $2.1 million   Units: 5.9 million   Price: $0.35 (unit)   Shares...
BC Week In Review | May 17, 2010
Clinical News

Triolex: Phase IIa data

Data from the first and second stages of the double-blind, 2-stage, U.S. Phase IIa HE3286-0401 trial showed that 5 mg twice-daily oral Triolex missed the primary endpoint of significantly reducing HbA1c from baseline to week...
Items per page:
1 - 10 of 174